These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 12671967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA, Rudd MT, Nguyen KT, McIntyre CJ, Romano JJ, Bush KJ, Varga SL, Ross CW, Carroll SS, DiMuzio J, Stahlhut MW, Olsen DB, Lyle TA, Vacca JP, Liverton NJ.
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P, Peterson SD, Kerblom E, Gossas T, Sabnis YA, Fransson R, Lindeberg G, Helena Danielson U, Karlén A, Sandström A.
    Bioorg Med Chem; 2007 Feb 01; 15(3):1448-74. PubMed ID: 17113777
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX, Njoroge FG.
    Prog Med Chem; 2010 Feb 01; 49():1-36. PubMed ID: 20855037
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO, Bäck M, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5136-51. PubMed ID: 16675222
    [Abstract] [Full Text] [Related]

  • 16. The effect of the P1 side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease.
    Kawai SH, LaPlante SR, Llinàs-Brunet M, Hucke O.
    Future Med Chem; 2010 Jul 01; 2(7):1073-81. PubMed ID: 21426157
    [Abstract] [Full Text] [Related]

  • 17. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S, Njoroge FG.
    Expert Opin Ther Pat; 2009 Sep 01; 19(9):1277-303. PubMed ID: 19563268
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.